View in EDS

Development of bicistronic plasmids and fusion proteins for clinical translation of tumor immune reprogramming.

Saved in:
Bibliographic Details
Title: Development of bicistronic plasmids and fusion proteins for clinical translation of tumor immune reprogramming.
Authors: Yang J; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Translational ImmunoEngineering Center, Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA., Chen SS; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Translational ImmunoEngineering Center, Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA., Idnani E; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Translational ImmunoEngineering Center, Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA., Shannon SR; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Translational ImmunoEngineering Center, Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA., Luly K; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Translational ImmunoEngineering Center, Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA., Fabilane CS; Translational ImmunoEngineering Center, Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA., Wilson DS; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Translational ImmunoEngineering Center, Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA., Spangler JB; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Translational ImmunoEngineering Center, Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Department of Chemical & Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218, USA.; Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Department of Molecular Microbiology & Immunology, Johns Hopkins University School of Public Health, Baltimore, MD 21205, USA., Tzeng SY; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Translational ImmunoEngineering Center, Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA., Green JJ; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Translational ImmunoEngineering Center, Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Department of Chemical & Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218, USA.; Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.; Department of Materials Science & Engineering, Johns Hopkins University, Baltimore, MD 21218, USA.; Institute for NanoBioTechnology and the Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD 21231, USA.
Source: Molecular therapy. Advances [Mol Ther Adv] 2026 Feb 28; Vol. 34 (2), pp. 201708. Date of Electronic Publication: 2026 Feb 28 (Print Publication: 2026).
Publication Type: Journal Article
Journal Info: Country of Publication: United States NLM ID: 9919257804006676 Publication Model: eCollection Cited Medium: Print ISSN: 3117-387X (Print) Linking ISSN: 3117387X NLM ISO Abbreviation: Mol Ther Adv Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42137591
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Development of bicistronic plasmids and fusion proteins for clinical translation of tumor immune reprogramming.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Yang+J%22">Yang J</searchLink>; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Translational ImmunoEngineering Center, Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.<br /><searchLink fieldCode="AU" term="%22Chen+SS%22">Chen SS</searchLink>; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Translational ImmunoEngineering Center, Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.<br /><searchLink fieldCode="AU" term="%22Idnani+E%22">Idnani E</searchLink>; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Translational ImmunoEngineering Center, Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.<br /><searchLink fieldCode="AU" term="%22Shannon+SR%22">Shannon SR</searchLink>; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Translational ImmunoEngineering Center, Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.<br /><searchLink fieldCode="AU" term="%22Luly+K%22">Luly K</searchLink>; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Translational ImmunoEngineering Center, Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.<br /><searchLink fieldCode="AU" term="%22Fabilane+CS%22">Fabilane CS</searchLink>; Translational ImmunoEngineering Center, Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.<br /><searchLink fieldCode="AU" term="%22Wilson+DS%22">Wilson DS</searchLink>; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Translational ImmunoEngineering Center, Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.<br /><searchLink fieldCode="AU" term="%22Spangler+JB%22">Spangler JB</searchLink>; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Translational ImmunoEngineering Center, Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Department of Chemical & Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218, USA.; Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Department of Molecular Microbiology & Immunology, Johns Hopkins University School of Public Health, Baltimore, MD 21205, USA.<br /><searchLink fieldCode="AU" term="%22Tzeng+SY%22">Tzeng SY</searchLink>; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Translational ImmunoEngineering Center, Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.<br /><searchLink fieldCode="AU" term="%22Green+JJ%22">Green JJ</searchLink>; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Translational ImmunoEngineering Center, Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Department of Chemical & Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218, USA.; Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.; Department of Materials Science & Engineering, Johns Hopkins University, Baltimore, MD 21218, USA.; Institute for NanoBioTechnology and the Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD 21231, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229919257804006676%22">Molecular therapy. Advances</searchLink> [Mol Ther Adv] 2026 Feb 28; Vol. 34 (2), pp. 201708. <i>Date of Electronic Publication: </i>2026 Feb 28 (<i>Print Publication: </i>2026).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Country of Publication: </i>United States <i>NLM ID: </i>9919257804006676 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>3117-387X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%223117387X%22">3117387X </searchLink><i>NLM ISO Abbreviation: </i>Mol Ther Adv <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42137591
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.omta.2026.201708
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 201708
    Titles:
      – TitleFull: Development of bicistronic plasmids and fusion proteins for clinical translation of tumor immune reprogramming.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Yang J
      – PersonEntity:
          Name:
            NameFull: Chen SS
      – PersonEntity:
          Name:
            NameFull: Idnani E
      – PersonEntity:
          Name:
            NameFull: Shannon SR
      – PersonEntity:
          Name:
            NameFull: Luly K
      – PersonEntity:
          Name:
            NameFull: Fabilane CS
      – PersonEntity:
          Name:
            NameFull: Wilson DS
      – PersonEntity:
          Name:
            NameFull: Spangler JB
      – PersonEntity:
          Name:
            NameFull: Tzeng SY
      – PersonEntity:
          Name:
            NameFull: Green JJ
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 28
              M: 02
              Text: 2026 Feb 28
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 3117-387X
          Numbering:
            – Type: volume
              Value: 34
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Molecular therapy. Advances
              Type: main
ResultId 1